Springer Nature continues to be neutral with regards to jurisdictional claims in printed maps and institutional affiliations. Bortezomib is usually a reversible proteasome inhibitor which was approved by the United States Food and Drug Administration (FDA) to be used in relapsed/refractory MM in 2003 and additional approved for frontline therapy https://josephn777kct7.bleepblogs.com/profile